Latest Insider Transactions at Vallon Pharmaceuticals, Inc. (VLON)
This section provides a real-time view of insider transactions for Vallon Pharmaceuticals, Inc. (VLON). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vallon Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vallon Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 21
2023
|
Albert Agro Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
172,189
+50.0%
|
-
|
|
Apr 21
2023
|
Walter Marc Hertz Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
385,510
+50.0%
|
-
|
|
Apr 21
2023
|
Vipin Chaturvedi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
172,189
+50.0%
|
-
|
|
Dec 13
2022
|
Marella Thorell Director |
SELL
Other acquisition or disposition
|
Direct |
28,517
-75.0%
|
-
|
|
Jul 01
2022
|
Marella Thorell Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,023
+50.0%
|
-
|
|
Jun 04
2021
|
Leanne M. Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,508
+19.44%
|
$6,032
$4.08 P/Share
|
|
Jun 03
2021
|
Leanne M. Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,085
+18.62%
|
$4,340
$4.05 P/Share
|
|
Jun 02
2021
|
Leanne M. Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,657
+50.0%
|
$14,628
$4.0 P/Share
|
|
May 26
2021
|
Joseph E Payne Director |
BUY
Open market or private purchase
|
Direct |
6,800
+27.98%
|
$27,200
$4.5 P/Share
|
|
May 25
2021
|
Joseph E Payne Director |
BUY
Open market or private purchase
|
Direct |
10,700
+50.0%
|
$32,100
$3.85 P/Share
|
|
Feb 12
2021
|
David Charles Baker Director |
BUY
Open market or private purchase
|
Direct |
1,000
+10.16%
|
$8,000
$8.0 P/Share
|
|
Feb 12
2021
|
David Charles Baker Director |
BUY
Other acquisition or disposition
|
Direct |
7,843
+50.0%
|
$47,058
$6.4 P/Share
|
|
Feb 12
2021
|
Pharma Gmb H Salmon > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
47,063
+50.0%
|
$282,378
$6.4 P/Share
|
|
Feb 12
2021
|
Richard Ammer Director |
BUY
Other acquisition or disposition
|
Indirect |
47,063
+50.0%
|
$282,378
$6.4 P/Share
|